|
The following stocks are the leading risers and fallers among London Main Market small-caps on Monday. ---------- SMALL-CAP - WINNERS ---------- Defence Holdings PLC, up 18% at 1.30 pence, 12-month range 0.14p-4.90p. The defence technology firm says it ‘continues to gather momentum’. ‘With two sovereign-AI programmes progressing toward deployment, deepening integration with global technology partners, a strengthened balance sheet, and senior leadership capacity being reinforced, the company remains well positioned to convert capability into sustained operational and commercial value across mission-critical defence programmes,’ it says. For the six months to September 30, Defence Holdings generates no revenue and reports a pretax loss of £3.7 million. In the 18 months to March 31, it reported revenue of £4.3 million and a pretax loss of £1.0 million. ---------- Ferrexpo PLC, up 5.4% at 76.11p, 12-month range 41.30p-115.00p. Shares in the iron ore pellet producer rise on Ukraine-Russia peace hope. Ferrexpo operates in Ukraine. US and Ukrainian envoys issued a joint statement on Sunday that hailed ‘productive and constructive’ talks in Miami, but did not announce any apparent breakthrough in efforts to end the war with Russia, AFP reports. Top representatives of Ukraine and Russia, as well as Kyiv’s European allies, have been in southern Florida over the past several days for a series of separate talks hosted by US President Donald Trump’s special envoy, Steve Witkoff. Shares in Ferrexpo have risen by roughly two thirds over the past six months, but are down by about a quarter year-to-date and have slumped some 70% since the onset of the war. ---------- SMALL-CAP - LOSERS ---------- Solvonis Therapeutics PLC, down 9.4% at 0.25p, 12-month range 0.11p-0.40p. The biopharmaceutical company, focused on central nervous system disorders, says 2025 has been ‘transformative’ and has ‘clearly defined catalysts’ in 2026, including possible regulatory boosts and partnerships. ‘Solvonis enters 2026 with a diversified CNS pipeline spanning late-stage clinical development, near-term regulatory catalysts, and early-stage discovery programmes supported by external validation and non-dilutive funding pathways,’ Solvonis says. The shares are up around 21% so far this year. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
